TrialStatistics in medicine2022

Surv-CRM-12: A Bayesian phase I/II survival CRM for right-censored toxicity endpoints with competing disease progression.

Anaïs Andrillon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.